You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Potent and selective mTOR inhibitor (IC50 = 2.1 nM). Displays 800-fold cellular selectivity for mTOR over PI3K (cellular EC50 values are 0.25 and 200 nM for mTOR and PI3K respectively). Activates autophagy. Orally available.
Sold under license from Whitehead Institute for Biomedical Research.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 432.4. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.2 mM||11.56 mL||57.82 mL||115.63 mL|
|1 mM||2.31 mL||11.56 mL||23.13 mL|
|2 mM||1.16 mL||5.78 mL||11.56 mL|
|10 mM||0.23 mL||1.16 mL||2.31 mL|
References are publications that support the biological activity of the product.
Liu et al (2011) Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J.Med.Chem. 54 1473 PMID: 21322566
Simioni et al (2014) Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget 30 10034 PMID: 25296981
Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. PMID: 28529316
If you know of a relevant reference for Torin 2, please let us know.
View Related Products by Product Action
Keywords: Torin 2, Torin 2 supplier, Torin2, mtor, mammalian, target, rapamycin, selective, inhibitors, inhibits, mTOR, Autophagy, 4248, Tocris Bioscience
15 Citations for Torin 2
Citations are publications that use Tocris products. Selected citations for Torin 2 include:
Montané and Menand (2013) ATP-competitive mTOR kinase inhibitors delay plant growth by triggering early differentiation of meristematic cells but no developmental patterning change. J Virol 64 4361 PMID: 23963679
Soliman et al (2017) Effects of MET and a Mammalian Target of Rapamycin (mTOR) ATP-Competitive Inhibitor on Targeted Metabolomics in Pancreatic Cancer Cell Line. Metabolomics (Los Angel) 6 PMID: 28217402
Al-Ali et al (2017) The mTOR Substrate S6 Kinase 1 (S6K1) Is a Negative Regulator of Axon Regeneration and a Potential Drug Target for Central Nervous System Injury. J Neurosci 37 7079 PMID: 28626016
Ginzberg et al (2018) Cell size sensing in animal cells coordinates anabolic growth rates and cell cycle progression to maintain cell size uniformity. Elife 7 PMID: 29889021
Zullo et al (2014) Mammalian target of Rapamycin inhibition and mycobacterial survival are uncoupled in murine macrophages. Cell 15 4 PMID: 24528777
Brown et al (2014) Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis. Mol Biol Cell 88 13149 PMID: 25187540
Hwang et al (2013) Protein phosphatase 2A isoforms utilizing Aβ scaffolds regulate differentiation through control of Akt protein. J Biol Chem 288 32064 PMID: 24052256
Feehan et al (2018) Inhibition of mTORC2 enhances UVB-induced apoptosis in keratinocytes through a mechanism dependent on the FOXO3a transcriptional target NOXA but independent of TRAIL. Cell Signal 52 35 PMID: 30172026
Jennewein et al (2016) Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas. Oncotarget 7 20016 PMID: 26956048
Martin et al (2014) mTORC1 and JNK coordinate phosphorylation of the p70S6K1 autoinhibitory domain in skeletal muscle following functional overloading. Am J Physiol Endocrinol Metab 306 E1397 PMID: 24801387
Toops et al (2015) Cholesterol-mediated activation of acid sphingomyelinase disrupts autophagy in the retinal pigment epithelium. Nat Commun 26 41640 PMID: 25378587
Yu et al (2015) PI3K/mTORC2 regulates TGF-β/AVNsignalling by modulating Smad2/3 activity via linker phosphorylation. BMC Biochem 6 7212 PMID: 25998442
Hussain et al (2015) Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of cisp. in Epithelial Ovarian Cancer. Mol Med 21 466 PMID: 26023849
Han et al (2014) Parallel measurement of dynamic changes in translation rates in single cells. Nat Methods 11 86 PMID: 24213167
Ahmed et al (2014) High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma. Carcinogenesis 35 1564 PMID: 24583924
Do you know of a great paper that uses Torin 2 from Tocris? Please let us know.
Reviews for Torin 2
There are currently no reviews for this product. Be the first to review Torin 2 and earn rewards!
Have you used Torin 2?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.